Invention Grant
- Patent Title: Compounds for enzyme inhibition
- Patent Title (中): 用于酶抑制的化合物
-
Application No.: US11596028Application Date: 2005-05-09
-
Publication No.: US08088741B2Publication Date: 2012-01-03
- Inventor: Mark S. Smyth , Guy J. Laidig , Ronald T. Borchardt , Barry A. Bunin , Craig M. Crews , John H. Musser , Kevin D. Shenk , Peggy A. Radel
- Applicant: Mark S. Smyth , Guy J. Laidig , Ronald T. Borchardt , Barry A. Bunin , Craig M. Crews , John H. Musser , Kevin D. Shenk , Peggy A. Radel
- Applicant Address: US CA South San Francisco
- Assignee: Onyx Therapeutics, Inc.
- Current Assignee: Onyx Therapeutics, Inc.
- Current Assignee Address: US CA South San Francisco
- Agency: Fish & Richardson P.C.
- International Application: PCT/US2005/016335 WO 20050509
- International Announcement: WO2005/111008 WO 20051124
- Main IPC: A61K38/06
- IPC: A61K38/06 ; C12Q1/34

Abstract:
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsinlike activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
Public/Granted literature
- US20080090785A1 Compounds For Enzyme Inhibition Public/Granted day:2008-04-17
Information query
IPC分类: